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Abstract
Background Intestinal microbiota have been suggested to play an important role in the pathogenesis of obesity and type 2
diabetes. Bariatric surgery improves both conditions and has been associated with changes in intestinal microbiota com-
position. We investigated the effect of a nonsurgical bariatric technique on intestinal microbiota composition in relation to
metabolic improvement.
Methods Seventeen patients with obesity and type 2 diabetes were treated with the nonsurgical duodenal–jejunal bypass
liner, which excludes the proximal 60 cm small intestine from food. Fecal samples as well as metabolic parameters reflecting
obesity and type 2 diabetes were obtained from the patients at baseline, after 6 months with the device in situ, and 6 months
after explantation.
Results After 6 months of treatment, both obesity and type 2 diabetes had improved with a decrease in weight from 106.1
[99.4–123.5] to 97.4 [89.4–114.0] kg and a decrease in HbA1c from 8.5% [7.6–9.2] to 7.2% [6.3–8.1] (both p < 0.05). This
was paralleled by an increased abundance of typical small intestinal bacteria such as Proteobacteria, Veillonella, and
Lactobacillus spp. in feces. After removal of the duodenal–jejunal bypass liner, fecal microbiota composition was similar to
that observed at baseline, despite persistent weight loss.
Conclusion Improvement of obesity and type 2 diabetes after exclusion of the proximal 60 cm small intestine by treatment
with a nonsurgical duodenal–jejunal bypass liner may be promoted by changes in fecal microbiota composition.
Introduction
The human gastrointestinal tract is inhabited by an enor-
mous number and diversity of mainly anaerobic micro-
organisms, referred to as the intestinal microbiota [1]. The
collective genome of our intestinal microbiota, the intestinal
metagenome, exceeds the human genome by a magnitude of
more than 100 [2]. Recent evidence suggests that the
intestinal microbiota play an important role in the patho-
genesis of obesity and type 2 diabetes [3–5]. Following the
observation that lean germ-free mice did not gain weight on
a high-fat diet, it was reported that colonization of these
sterile mice with intestinal microbiota from obese mice led
to body fat increases and insulin resistance, while this was
not observed after colonization with the microbiota from
lean donor mice [6–8]. Furthermore, both genetically and
diet-induced obese mice carried a different intestinal
microbiota composition compared to lean controls. In
addition, obesity was associated with an increased ratio of
the two most dominant phyla within the gut microbiota, the
Firmicutes and the Bacteroidetes [9, 10]. It has been sug-
gested that in these preclinical models, an increased capa-
city of the ‘obese microbiota’ to harvest energy from
ingested food and to facilitate storage of these calories in
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host adipose tissue could explain the association between
gut microbiota composition and the development of obesity
and possibly type 2 diabetes [6, 7].
Although the gut microbiota, metabolic rate, and dietary
habits of humans and mice show large differences [11],
some observations made in mice could be partly reproduced
in human studies. In particular, it was observed that an
unusual gut microbiota composition was associated with
obesity [9, 12–14]. In addition, changes in microbiota
composition have been found to be related to weight loss
[13, 15–17]. In line with these findings, bariatric surgery,
the most durable obesity and type 2 diabetes treatment, has
also been associated with changes in microbiota composi-
tion [18–20]. Moreover, two studies have shown that fecal
transplantation of intestinal microbiota from lean donors
into obese human subjects transiently increases insulin
sensitivity without affecting body weight [21, 22]. A spe-
cific fiber treatment that affected the intestinal microbiota
was also shown to improve insulin resistance [23]. These
data indicate that intestinal microbiota might promote the
development of obesity and type 2 diabetes in humans as
well. Since both obesity and the metabolic syndrome have
been shown to improve after implantation of the duodenal–
jejunal bypass liner (DJBL, GI Dynamics, Boston, MA), a
nonsurgical bariatric device excluding the proximal part of
the small intestine [24–27], we investigated intestinal
microbiota composition in relation to metabolic changes
induced by the DJBL.
Methods
Study design
Seventeen subjects were studied before and during DJBL
treatment. Additionally, six patients were studied 6 months
after removal of the DJBL. In eight patients, the device was
explanted after 6 months; in nine patients, explantation was
conducted after 12 months, as previously described [24]. At
each time point (prior to DJBL (B), 6 months after initiation
of DJBL treatment (6M), and 6 months after explantation
(6MPE)), body weight was determined and venous blood
samples were obtained in the outpatient clinic. Plasma
levels of HbA1c, glucose, and insulin were determined
routinely at the Department of Clinical Chemistry. In
addition, a standardized meal tolerance test was performed:
blood samples were drawn after an overnight fast; thereafter
a standard liquid meal (Ensure Plus, Abbott Laboratories,
IL; 333 mL, 500 kcal, 20.8 g protein, 67.3 g carbohydrates,
and 16.4 g fat) was consumed, followed by collection of
blood samples in EDTA with aprotinin at up to 240 min
postprandially. Samples were immediately cooled, cen-
trifuged, and stored at −80 °C until further analysis. Fecal
samples were collected within 24 h prior to the visits and
were kept refrigerated until arrival at the outpatient clinic
where the samples were immediately stored at −20 °C until
further analysis. Throughout the study, subjects were pre-
scribed a diet with a maximum of 1200 kcal for women and
1500 kcal for men.
Subjects
Subjects were treated with the DJBL at the Maastricht
University Medical Center, Maastricht or the Zuyderland
Medical Centre, Heerlen, the Netherlands. Inclusion criteria
were: age between 18 and 65 years; body mass index (BMI)
between 30 and 50 kg/m2; duration of type 2 diabetes <10
years. Main exclusion criteria were: use of weight loss
medication or anti-inflammatory drugs; history of inflam-
matory diseases; exclusion criteria regarding safety of
DJBL placement or DJBL compatibility. The study was
approved by the Medical Ethics Committee of both centers
and conducted according to the revised version of the
Declaration of Helsinki (October 2008, Seoul). Written
informed consent was obtained from every patient before
study participation.
DJBL procedure
The DJBL is a 60-cm long impermeable liner which has
been developed to mimic the intestinal bypass component
of the Roux-en-Y gastric bypass (RYGB) in a nonsurgical
way. The DJBL was delivered and retrieved endoscopically
as previously described [24]. In brief, a gastroduodenal
endoscopy was performed under general anesthesia. A
guide wire was placed into the duodenum over which the
encapsulated DJBL was directed through the pylorus into
the duodenal bulb. The DJBL was advanced into the small
intestine, followed by deployment of the anchor in the
duodenal bulb. Correct positioning and patency of the
DJBL were verified under fluoroscopy. Explantation was
performed endoscopically under general anesthesia using a
custom retrieval system containing a grasper and a retrieval
hood. By grasping the wires on the anchor, the anchor
collapsed and was pulled into the retrieval hood on top of
the endoscope. After verification of the collapsed anchor by
fluoroscopy, the device was removed.
Fecal microbiota profiling
DNA was isolated as previously described [28] and the
intestinal microbiota composition was determined using the
Human Intestinal Tract chip (HITChip), a phylogenetic
DNA microarray containing over 5000 probes based on 16S
rRNA gene sequences of over 1100 intestinal bacterial
phylotypes. This microarray has been extensively used for
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the study of the microbiota in different conditions, including
obesity and related diseases [12, 21], and it identifies both
variation and relative quantity of the human intestinal tract
communities [29]. Hybridizations were performed in
duplicate with samples labeled with Cy3 and Cy5 dyes.
Slides were scanned and the data were extracted from the
microarray images using the Agilent Feature Extraction
software, version 10.7.3.1 (http://www.agilent.com). Array
normalization was performed as previously described [29,
30] using a set of R-based scripts (http://r-project.org) in
combination with a custom designed database that runs
under the MySQL database management system
(http://www.mysql.com). This was implemented on both
dyes for each sample, and duplicate hybridizations with a
Pearson correlation over 0.98 were considered for further
analysis. Complete linkage was used for the construction of
hierarchical clusters of the total microbiota probe profiles,
while the distance matrix between the samples was based on
Pearson correlation. The bacterial diversity of the fecal
samples was assessed by Shannon’s index of diversity using
the HITChip probe level [31].
Statistical analysis
Total area under the curve (AUC) of glucose and insulin
was calculated using the trapezoidal method. HOMA-IR
was calculated with the following formula: fasting glucose
(mmol/L) × fasting insulin (mU/L) / 22.5. For comprehen-
sive multivariate statistical analyses, Canoco software for
Windows 5.0 was used [32]. Redundancy analysis (RDA)
was used to assess correlations between the microbial
groups detected by the HITChip analysis in function of
sample characteristics. The log transformed hybridization
signals of 130 genus-level phylogenetic groups were used
as biological variables. As environmental variables, we
included BMI, weight, excess weight loss (EWL), HbA1c,
fasting glucose, fasting insulin, AUC glucose, AUC insulin,
HOMA-IR, and sample source (i.e., a factor combination of
treatment and time). Monte Carlo permutation testing
(MCPT) as implemented in the Canoco software package
was used to assess statistical significance of these variables
in the dataset. The bacterial composition of the samples was
compared at the phylum level (Class level for the Firmi-
cutes) and at the approximate genus level (130 phylogenetic
groups with more than 90% 16S rRNA gene sequence
similarity [29]); using the Wilcoxon signed-rank test cor-
rected for false discovery rate for which corrected p < 0.05
was considered significant. Differences in microbiota
diversity were assessed by Student’s t test. Differences in
weight and plasma parameters over time were assessed with
the Wilcoxon Matched-pairs Signed Rank test. Values were
considered significant at corrected p values <0.05. Data are
presented as median and interquartile range.
Results
Metabolic changes initiated by DJBL treatment
Before implantation, patients had a median body weight of
106.1 [99.4–123.5] kg, a BMI of 35.2 [32.2–40.9] kg/m2,
and an HbA1c of 8.5% [7.6–9.2]. Fasting glucose and
insulin levels were 9.8 [8.9–12.8] mmol/L and 16.4 [10.1–
21.3] IU/L, respectively. HOMA-IR was 7.3 [5.0–10.4].
Changes after 6 months of DJBL treatment are depicted
in Fig. 1. Median body weight had decreased to 97.4 [89.4–
114.0] kg (p < 0.05, Fig. 1a). This corresponds to a BMI of
31.5 [29.5–38.1] kg/m2 and an EWL of 18.3% [10.2–26.4]
(both p < 0.05, Fig. 1b, c). HbA1c had decreased to 7.2%
[6.3–8.1] (p < 0.05, Fig. 1d). In addition, fasting glucose
levels, fasting insulin levels, and HOMA-IR decreased to
7.8 [7.1–8.7] mmol/L, 10.8 [8.4–16.1] IU/L, and 3.5 [2.5–
6.4], respectively (all p < 0.05, Fig. 1e–g). Moreover, the
glucose response to a meal as reflected by the AUC for
glucose had decreased (Fig. 1h, p < 0.05). The AUC for
insulin was not significantly changed (Fig. 1i, p= 0.07).
Taken together, these data show that DJBL treatment sig-
nificantly improved body weight and type 2 diabetes
parameters.
DJBL treatment induces gut microbiota composition
alterations
Fecal microbiota composition was profoundly affected by
DJBL treatment, as shown in Table 1. The DJBL inter-
vention was notably associated with several changes within
the Firmicutes phylum. Specifically, an ~25-fold increased
relative abundance of Lactobacillus gasseri et rel., an ~11-
fold increase in Lactobacillus plantarum et rel., as well as
an almost 7-fold increase in Veillonella spp. were observed.
Furthermore, many genera within the Proteobacteria phy-
lum were increased in relative abundance by the DJBL
treatment. The relative levels of Enterobacter aerogenes et
rel. (~8-fold), Escherichia coli et rel. (~5-fold), Klebsiella
pneumoniae et rel. (~12-fold), and Serratia (~6-fold) all
increased after 6 months of DJBL treatment. In addition, the
diversity of the fecal microbiota composition, as reflected
by the Shannon diversity index, tended to increase from 5.4
[5.2–5.7] to 5.8 [5.4–5.9] by DJBL treatment (Fig. 2, p=
0.053).
Relationship between DJBL-induced metabolic
improvement and microbiota composition
Next, we studied the relationship between changes in
microbiota composition and changes in body weight and
metabolic parameters induced by DJBL treatment. Clus-
tering by RDA indicated that the DJBL-induced
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improvement in body weight and type 2 diabetes para-
meters negatively correlated with the relative abundance
of Clostridium cluster XIVa and other Firmicutes (Fig. 3).
In addition, a positive correlation was found between
EWL and the relative abundance of Bacilli, Proteo-
bacteria, and Bacteroidetes. This suggests that the meta-
bolic improvement as observed after DJBL treatment is
associated with rather specific changes in gut microbiota
composition.
Additional analyses further revealed that changes in
specific bacterial groups correlate with the decreases in
obesity and type 2 diabetes-related parameters (Fig. 4). For
example, reductions in fasting glucose and HbA1c strongly
correlated with increases in relative abundance of members
of the Firmicutes phylum, specifically bacteria related to
Ruminococcus callidus and Oscillospira guillermondii,
respectively. Furthermore, changes in several other bacterial
groups correlated negatively with EWL. As displayed in
Fig. 4, positive correlations were found between EWL and
both bacteria related to L. gasseri and L. plantarum, which
abundance was greatly increased after DJBL treatment.
Additional positive correlations were found between EWL
and members from the Proteobacteria phylum: bacteria
related to E. coli, Yersinia, K. pneumoniae, and E. aero-
genes. Thus, changes in specific bacterial groups were
associated with the metabolic improvement induced by
DJBL treatment.
Reversal of microbiota alterations after DJBL
explantation
Six months after explantation of the DJBL, the fecal
microbiota composition of the patients was similar to that
observed before DJBL implantation (Fig. 3). In addition, no
significant difference was found between the Shannon
diversity index before implantation vs. 6 months post-
explantation (5.4 [5.2–5.7] vs. 5.5 [5.4–5.6], Fig. 5a, p=
0.87). In contrast, 6 months after explantation, EWL,
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Fig. 1 Effects of DJBL treatment on metabolic parameters. a The body
weight of patients before and 6 months after initiation of DJBL
treatment. b BMI changes. c The excess weight loss after 6 months of
DJBL treatment. d The HbA1c concentrations. e, f The fasting glucose
and insulin levels obtained at baseline and at 6 months after initiation
of DJBL treatment. g The changes in HOMA-IR initiated by DJBL
treatment. h, i The area under the curve calculations for glucose and
insulin, respectively. An asterisk (*) indicates p < 0.05
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HOMA-IR, and the AUC for glucose remained significantly
improved when compared to baseline (Fig. 5d, h, i). This
indicates a sustained effect of the DJBL after explantation
of the device, independent of microbiota changes.
Discussion
Gut microbiota are considered to play an important role in
the development of obesity and its related comorbidities. In
the current study, the relationship between a reduction of
obesity and type 2 diabetes-related parameters following a
nonsurgical bariatric and metabolic technique and the
resulting impact on intestinal microbiota composition were
investigated. Our results indicate that metabolic improve-
ment after a bariatric intervention excluding the proximal
small intestine correlates with changes in colonic micro-
biota composition.
The DJBL can be considered to mimic the intestinal
bypass component of the conventional RYGB. Interest-
ingly, the current data regarding changes in microbiota
composition in relation to weight loss and metabolic
improvement after initiation of DJBL treatment are in line
with previous results reported in the context of RYGB
surgery. Changes in gut microbiota after RYGB were
Fig. 2 Changes in Shannon diversity index of the microbiota at
baseline and 6 months after initiation of DJBL treatment. Data are
presented as median and interquartile range. The p-value is 0.053
Table 1 Significant differences of genus-like bacterial groups after DJBL intervention
Relative abundance
(% ± SD)
Significance
Phylum Phylum/Class Genus-like Baseline 6 months p-Value Corrected p-value
Bacteroidetes Bacteroidetes Bacteroides uniformis et rel 0.26 ± 0.47 0.56 ± 0.88 0.029* 0.347
Firmicutes Bacilli Lactobacillus gasseri et rel 0.16 ± 0.08 3.95 ± 4.14 0.000** 0.000
Lactobacillus plantarum et rel 0.31 ± 0.42 3.55 ± 3.84 0.000** 0.001
Clostridium cluster IV Clostridium cellulosi et rel 1.74 ± 3.38 2.00 ± 2.46 0.134 0.738
Oscillospira guillermondii et rel 2.69 ± 6.52 3.87 ± 3.79 0.022* 0.291
Sporobacter termitidis et rel 1.37 ± 2.19 2.59 ± 1.83 0.011* 0.164
Clostridium cluster IX Dialister 0.39 ± 0.61 0.29 ± 0.30 0.483 0.747
Megamonas hypermegale et rel. 0.11 ± 0.24 0.03 ± 0.02 0.045* 0.449
Veillonella 0.07 ± 0.07 0.47 ± 0.43 0.000** 0.000
Clostridium cluster XIVa Bryantella formatexigens et rela 1.55 ± 1.03 1.29 ± 0.89 0.424 0.738
Clostridium nexile et relb 1.69 ± 1.44 1.26 ± 0.87 0.613 0.813
Coprococcus eutactus et rel. 5.88 ± 6.93 2.47 ± 1.81 0.126 0.738
Eubacterium hallii et rel 1.07 ± 0.98 0.50 ± 0.40 0.062 0.534
Ruminococcus obeum et relc 15.66 ± 12.76 7.56 ± 7.90 0.038* 0.412
Proteobacteria Proteobacteria Enterobacter aerogenes et rel ± 0.28 ± 0.42 2.37 ± 3.85 0.000** 0.000
Escherichia coli et rel 0.64 ± 1.40 3.37 ± 4.14 0.001** 0.016
Klebsiella pneumoniae et rel 0.24 ± 0.38 2.84 ± 4.57 0.000** 0.002
Serratia 0.05 ± 0.08 0.31 ± 0.44 0.002** 0.039
Yersinia et rel 0.06 ± 0.03 0.23±0.31 0.003* 0.055
*p < 0.05; **p < 0.05 after FDR correction. Highlighted in italic and in bold groups increased and decreased, respectively, after 6 months of DJBL
treatment
Some species are known by different names or have recently been renamed
aBryantella formatexigens=Marvinbryantia formatexigens
bClostriudium nexile= Tyzzerella nexilis
cRuminococcus obeum= Blautia obeum ± Enterobacter aerogenes= Klebsiella aerogenes
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shown to be associated with weight loss and metabolic
improvement [18, 20].
As shown in Table 1, the abundance of several members
of the Proteobacteria phylum was increased in feces after
DJBL implantation. In both animals and humans under-
going RYGB surgery, similar increases of Proteobacteria
have been reported [5, 18, 20, 33, 34]. An explanation for
this shift might be found in the effects of proximal small
intestinal exclusion. After DJBL implantation as well as
after RYGB, digestion and absorption of nutrients is
delayed to the mid-jejunum as the proximal small intestine
is excluded from alimentary flow [35]. As a result, undi-
gested nutrients will be available more distal in the small
intestine. This might relocate typical small intestinal
microbiota, such as Proteobacteria, to the colon. In line, we
observed a large increase of Veillonella, a frequently
encountered commensal in the human small intestine
belonging to the Firmicutes phylum [36], in the feces of
DJBL-treated subjects.
Next to these changes, DJBL treatment induced a
microbiota shift in favor of lactobacilli. Both bacteria rela-
ted to L. plantarum and L. gasseri increased greatly after
initiation of DJBL treatment. Interestingly, these and other
Lactobacillus spp. have previously been associated with
weight loss. In overweight/obese small animal models,
administration of L. plantarum caused body weight loss [8,
37]. Administration of fermented milk containing the pro-
biotic L. gasseri SBT2055 to humans also led to a decrease
in body weight and abdominal adiposity [38]. In addition,
trans-10,cis-12-conjugated linoleic acid-producing L.
Fig. 3 RDA plot of metabolic
parameters and microbiota
composition before and after
DJBL treatment. Redundancy
analysis of the association
between metabolic parameters
and the baseline microbiota
composition of patients (blue
dots), the microbiota
composition of patients after
6 months of DJBL intervention
(green dots), and 6 months post-
intervention (red dots). The
plotted first and second
ordinations axes explain 13%
and 5% of the variability in the
dataset. Associations are shown
with Bacilli and Proteobacteria,
Bacteroidetes, and Clostridium
cluster XIVa and other
Firmicutes. In addition,
correlations with all included
variables are shown, though
none were significant
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plantarum has been shown to have an antiobesity effect in
mice [39, 40]. This supports an important role for the
observed shift in favor of these lactobacilli in the
improvement of body weight following DJBL treatment.
Although speculative, the bloom in lactobacilli may also be
related to an increased availability of unabsorbed nutrients
in more distal intestinal segments. Importantly, at the spe-
cies level, different effects of lactobacilli on obesity have
been found [41–43]. However, since the HITChip does not
allow identification beyond genus level, these observations
cannot be verified in our study.
Shannon’s diversity index, representing the number of
different bacteria and their relative abundances in the fecal
microbiota composition, was increased by DJBL treatment,
similar to what has been reported after bariatric surgery
[44]. Importantly, decreased microbiota diversity has been
shown to be associated with both obesity and type 2 dia-
betes [45, 46]. In addition, the Shannon diversity index as
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Fig. 5 Changes in metabolic parameters after DJBL explantation. a
The Shannon diversity index at baseline and at 6 months post-
explantation. b Changes in patients’ weight. c Changes in BMI. d The
percentage of excess weight loss at 6 months post-explantation of the
DJBL. e HbA1c levels. f, g The fasting glucose and insulin levels,
respectively. h HOMA-IR levels. i, j The area under the curve cal-
culations for glucose and insulin at baseline and 6 months post-
explant, respectively. An asterisk (*) indicates p < 0.05
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calculated from the fecal samples obtained from non-obese
controls from our previous study was similar to the index
obtained from the samples collected 6 months after initia-
tion of DJBL treatment (5.9 [5.6–6.1] vs. 5.8 [5.4–5.9],
non-obese control vs. 6 months after initiation of DJBL
treatment, p= 0.15). This suggests a normalization of
intestinal microbial diversity by DJBL treatment.
Although the abundance of Clostridium cluster IV ten-
ded to be increased by DJBL treatment, the abundance of
Clostridium cluster XIVa tended to be decreased. Within
the Clostridium cluster IX, decreases as well as increases
were observed after DJBL treatment. Therefore, conclu-
sions regarding whether or not the observed changes within
the Clostridium clusters are beneficial are difficult to draw.
Similarly, the applicability of the recently proposed concept
of the impact of the gut redox status on chronic disease
conditions [47] remains to be determined. However, it is
conceivable that the DJBL alters oxygen consumption in the
proximal gastro-intestinal tract, potentially leading to an
increased fecal abundance of aerotolerant bacteria [48, 49].
After explantation of the DJBL, the EWL, HOMA-IR,
and the AUC for glucose during a meal tolerance test
remained significantly improved when compared to pre-
implantation, indicating a prolonged effect of DJBL treat-
ment. However, the microbiota composition returned to the
pre-implantation situation. This may suggest that the
metabolic improvement after DJBL treatment is indepen-
dent of microbiota composition changes. Alternatively, the
effect of DJBL treatment on gut microbiota composition
may primarily drive the initial improvement in glucose
homeostasis; other mechanisms, such as hormonal changes
[26, 50], may be responsible for the prolonged improve-
ment. Another explanation could be that the microbiota
changes are too small to be detected with the present
approach, as would be the case when they primarily affect
the small intestine microbes. However, the number of
patients studied at 6 months post explantation was small (n
= 6), warranting further investigation.
In summary, we have shown for the first time that
improvement of obesity and type 2 diabetes after exclusion
of the proximal small intestine by DJBL treatment is
associated with changes in microbiota composition. Our
data may provide keys to the pathogenesis of obesity and
type 2 diabetes, and further studies might lead to new
treatment modalities based on prebiotics and next-
generation probiotics.
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